** Shares of Israel-based medical device maker IceCure Medical ICCM.O fall 17% to $1.22 in afternoon trading, their biggest one-day percentage fall in more than a year
** ICCM says it expects the FDA to make a decision on its ProSense system, used for the treatment of a type of breast cancer, after Q1 2025
** Co previously expected FDA's decision by Q1 2025
** Co's ProSense provides a minimally invasive treatment option to destroy tumors by freezing them
** ICCM has risen 19.4% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))